Skip to main content

Advertisement

SpringerLink
Log in

Response to the letter to the editor “18F-FDG-PET/CT indication in patients affected by differentiated thyroid cancer with elevated serum thyroglobulin and negative whole-body scanning after therapy with 131I”

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 16 September 2020

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Albano D, Tulchinsky M, Dondi D, et al. Thyroglobulin doubling time offers a better threshold than thyroglobulin level for selecting optimal candidates to undergo localizing [18F]FDG PET/CT in non-iodine avid differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2020. https://doi.org/10.1007/s00259-020-04992-8.

  2. Rosario PW. 18F-FDG-PET/CT indication in patients affected by differentiated thyroid cancer with elevated serum thyroglobulin and negative whole-body scanning after therapy with 131I. Eur J Nucl Med Mol Imaging. 2020. https://doi.org/10.1007/s00259-020-05039-8.

  3. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.

    Article  Google Scholar 

  4. Piccardo A, Trimboli P, Foppiani L, et al. PET/CT in thyroid nodule and differentiated thyroid cancer patients. The evidence-based state of the art. Rev Endocr Metab Disord. 2019;20:47–64.

    Article  Google Scholar 

  5. Bertagna F, Albano D, Bosio G, et al. 18F-FDG-PET/CT in patients affected by differentiated thyroid carcinoma with positive thyroglobulin level and negative 131I whole body scan. It’s value confirmed by a bicentric experience. Curr Radiopharm. 2016;9:228–34.

    Article  CAS  Google Scholar 

  6. Abraham T, Schöder H. Thyroid cancer–indications and opportunities for positron emission tomography/computed emission tomography/computed tomography imaging. Semin Nucl Med. 2011;41:121–38.

    Article  Google Scholar 

  7. Giovanella L, Ceriani L, De Palma D, et al. Relationship between serum Tg and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinomas. Head Neck. 2012;34:626–31.

    Article  Google Scholar 

  8. Giovanella L, Trimboli P, Verburg FA, et al. Tg levels and Tg doubling time independently predict a positive (18) FFDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2013;40:874–80.

    Article  CAS  Google Scholar 

  9. Miyauchi A, Kudo T, Miya A, et al. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid. 2011;21:707–16.

    Article  Google Scholar 

  10. Zhang X, Higuchi T, Tomonaga H, et al. Early detection of progressive disease using thyroglobulin doubling-time in metastatic differentiated thyroid carcinoma treated with radioactive iodine. Nucl Med Comm. 2020;41:350–5.

    Article  CAS  Google Scholar 

  11. Albano D, Bertagna F, Bertoli M, et al. Possible delayed diagnosis and treatment of metastatic differentiated thyroid cancer by adopting the 2015 ATA guidelines. Eur J Endo. 2018;179:143–51.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine, University of Brescia and Spedali Civili Brescia, P.le Spedali Civili 1, 25123, Brescia, Italy

    Domenico Albano, Francesco Bertagna & Raffaele Giubbini

  2. Section of Nuclear Medicine, Department of Radiology, Milton S. Hershey Medical Center, Penn State Health, Hershey, PA, USA

    Mark Tulchinsky

Authors
  1. Domenico Albano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark Tulchinsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francesco Bertagna
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Raffaele Giubbini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Domenico Albano.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Additional information

This article is part of the Topical Collection on Letter to the Editor.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Albano, D., Tulchinsky, M., Bertagna, F. et al. Response to the letter to the editor “18F-FDG-PET/CT indication in patients affected by differentiated thyroid cancer with elevated serum thyroglobulin and negative whole-body scanning after therapy with 131I”. Eur J Nucl Med Mol Imaging 47, 2952–2953 (2020). https://doi.org/10.1007/s00259-020-05063-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-020-05063-8

Search

Navigation